|
1) Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-16
|
|
|
|
2) Watanabe H, Yamamoto S, Kunitoh H, et al. Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci. 2003; 94: 1015-20
|
|
|
|
|
3) Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-47
|
|
|
|
|
|
4) JCOG運営委員会. 固形がんの治療効果判定のための新ガイドライン(RECISTガイドライン)改訂版version 1. 1 — 日本語訳JCOG版 —. Excerpta Medica, Japan/Elsevier Science; 2010
|
|
|
|
|
|
5) WHO Handbook for Reporting Results of Cancer Treatment, Offset Publication, No. 48. Geneva(Switzerland): World Health Organization; 1979
|
|
|
|
|
|
6) Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-80
|
|
|
|
|
|
7) Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-86
|
|
|
|
|
|
8) Watanabe H, Kunitoh H, Yamamoto S, et al. Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients. Cancer Sci. 2006; 97: 214-8
|
|
|
|
|